Publication: International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management
Issued Date
2021-07-01
Resource Type
ISSN
18726623
Other identifier(s)
2-s2.0-85108608584
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Pain. Vol.162, (2021), S117-S124
Suggested Citation
Simon Haroutounian, Lars Arendt-Nielsen, Joletta Belton, Fiona M. Blyth, Louisa Degenhardt, Marta Di Forti, Christopher Eccleston, David P. Finn, Nanna B. Finnerup, Emma Fisher, Alexandra E. Fogarty, Ian Gilron, Andrea G. Hohmann, Eija Kalso, Elliot Krane, Mohammed Mohiuddin, R. Andrew Moore, Michael Rowbotham, Nadia Soliman, Mark Wallace, Nantthasorn Zinboonyahgoon, Andrew S.C. Rice International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. Vol.162, (2021), S117-S124. doi:10.1097/j.pain.0000000000002266 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78076
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management
Author(s)
Simon Haroutounian
Lars Arendt-Nielsen
Joletta Belton
Fiona M. Blyth
Louisa Degenhardt
Marta Di Forti
Christopher Eccleston
David P. Finn
Nanna B. Finnerup
Emma Fisher
Alexandra E. Fogarty
Ian Gilron
Andrea G. Hohmann
Eija Kalso
Elliot Krane
Mohammed Mohiuddin
R. Andrew Moore
Michael Rowbotham
Nadia Soliman
Mark Wallace
Nantthasorn Zinboonyahgoon
Andrew S.C. Rice
Lars Arendt-Nielsen
Joletta Belton
Fiona M. Blyth
Louisa Degenhardt
Marta Di Forti
Christopher Eccleston
David P. Finn
Nanna B. Finnerup
Emma Fisher
Alexandra E. Fogarty
Ian Gilron
Andrea G. Hohmann
Eija Kalso
Elliot Krane
Mohammed Mohiuddin
R. Andrew Moore
Michael Rowbotham
Nadia Soliman
Mark Wallace
Nantthasorn Zinboonyahgoon
Andrew S.C. Rice
Other Contributor(s)
Siriraj Hospital
UC San Diego Department of Anesthesiology
National Drug and Alcohol Research Centre
The University of Sydney School of Public Health
Queen's University, Centre for Neuroscience Studies, Kingston
Stanford University School of Medicine
University of Bath
Aarhus Universitet
South London and Maudsley NHS Foundation Trust
University of California, San Francisco
Washington University School of Medicine in St. Louis
Aalborg University
Indiana University Bloomington
Imperial College Faculty of Medicine
Queen’s University
King's College London
NUI Galway
Helsingin Yliopisto
IASP Global Alliance of Partners for Pain Advocacy task force
UC San Diego Department of Anesthesiology
National Drug and Alcohol Research Centre
The University of Sydney School of Public Health
Queen's University, Centre for Neuroscience Studies, Kingston
Stanford University School of Medicine
University of Bath
Aarhus Universitet
South London and Maudsley NHS Foundation Trust
University of California, San Francisco
Washington University School of Medicine in St. Louis
Aalborg University
Indiana University Bloomington
Imperial College Faculty of Medicine
Queen’s University
King's College London
NUI Galway
Helsingin Yliopisto
IASP Global Alliance of Partners for Pain Advocacy task force
Abstract
ABSTRACT: The President of the International Association for the Study of Pain established a task force on cannabis and cannabinoid analgesia to systematically examine the evidence on (1) analgesic pharmacology of cannabinoids and preclinical evidence on their efficacy in animal models of injury-related or pathological persistent pain; (2) the clinical efficacy of cannabis, cannabinoids, and cannabis-based medicines for pain; (3) harms related to long-term use of cannabinoids; as well as (4) societal issues and policy implications related to the use of these compounds for pain management. Here, we summarize key knowledge gaps identified in the task force outputs and propose a research agenda for generating high-quality evidence on the topic. The systematic assessment of preclinical and clinical literature identified gaps in rigor of study design and reporting across the translational spectrum. We provide recommendations to improve the quality, rigor, transparency, and reproducibility of preclinical and clinical research on cannabis and cannabinoids for pain, as well as for the conduct of systematic reviews on the topic. Gaps related to comprehensive understanding of the endocannabinoid system and cannabinoid pharmacology, including pharmacokinetics and drug formulation aspects, are discussed. We outline key areas where high-quality clinical trials with cannabinoids are needed. Remaining important questions about long-term and short-term safety of cannabis and cannabinoids are emphasized. Finally, regulatory, societal, and policy challenges associated with medicinal and nonmedicinal use of cannabis are highlighted, with recommendations for improving patient safety and reducing societal harms in the context of pain management.